JP2018535196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535196A5 JP2018535196A5 JP2018516843A JP2018516843A JP2018535196A5 JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5 JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- heavy chain
- domain
- antibody
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 59
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 6
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000047825 human ANGPT2 Human genes 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 37
- 125000000539 amino acid group Chemical group 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188060.6A EP3150637A1 (en) | 2015-10-02 | 2015-10-02 | Multispecific antibodies |
| EP15188060.6 | 2015-10-02 | ||
| EP16168918 | 2016-05-10 | ||
| EP16168918.7 | 2016-05-10 | ||
| PCT/EP2016/073410 WO2017055539A1 (en) | 2015-10-02 | 2016-09-30 | Multispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535196A JP2018535196A (ja) | 2018-11-29 |
| JP2018535196A5 true JP2018535196A5 (enExample) | 2019-11-07 |
| JP7239320B2 JP7239320B2 (ja) | 2023-03-14 |
Family
ID=57068100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516843A Active JP7239320B2 (ja) | 2015-10-02 | 2016-09-30 | 多重特異性抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170129962A1 (enExample) |
| EP (1) | EP3356420B1 (enExample) |
| JP (1) | JP7239320B2 (enExample) |
| CN (1) | CN108290958B (enExample) |
| WO (1) | WO2017055539A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| WO2010115589A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
| CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3489256B1 (en) | 2014-11-14 | 2021-03-17 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| CN107207579B (zh) | 2015-03-31 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3150636A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3589650A1 (en) * | 2017-03-02 | 2020-01-08 | Novartis AG | Engineered heterodimeric proteins |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| WO2019137552A1 (en) * | 2018-01-15 | 2019-07-18 | I-Mab | MODIFIED Cκ AND CH1 DOMAINS |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| US12269892B2 (en) | 2018-06-29 | 2025-04-08 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| US20220089722A1 (en) * | 2018-12-29 | 2022-03-24 | Nantong Yichen Biopharma. Co. Ltd. | Heterodimeric fusion protein |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2023139293A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
| CN119095873A (zh) | 2022-03-14 | 2024-12-06 | 拉姆卡普生物伽马股份公司 | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 |
| AU2023236386A1 (en) * | 2022-03-18 | 2024-10-10 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| WO2023201333A1 (en) | 2022-04-14 | 2023-10-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to ebola virus glycoprotein and their use |
| EP4522650A1 (en) | 2022-05-13 | 2025-03-19 | BioNTech SE | Rna compositions targeting hiv |
| EP4634228A1 (en) * | 2022-12-14 | 2025-10-22 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| WO2024138155A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| EP4642797A1 (en) | 2022-12-28 | 2025-11-05 | BioNTech SE | Rna compositions targeting hiv |
| WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025098100A1 (en) * | 2023-11-07 | 2025-05-15 | Biomap (Suzhou) Intelligent Technology Limited | Modified polypeptides for heteromultimer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE102005028778A1 (de) * | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7642282B2 (en) * | 2007-01-19 | 2010-01-05 | Milliken & Company | Whitening agents for cellulosic substrates |
| SI2235064T1 (sl) * | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| NZ608724A (en) | 2011-03-25 | 2015-12-24 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
| KR101261949B1 (ko) * | 2011-05-13 | 2013-05-13 | 현대자동차주식회사 | 촉매유닛 |
| US8901853B2 (en) * | 2012-07-11 | 2014-12-02 | Analog Devices, Inc. | Multi-string LED drive system |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| KR102381685B1 (ko) * | 2014-01-06 | 2022-04-01 | 에프. 호프만-라 로슈 아게 | 1가 혈액 뇌 장벽 셔틀 모듈 |
-
2016
- 2016-09-30 JP JP2018516843A patent/JP7239320B2/ja active Active
- 2016-09-30 CN CN201680069598.7A patent/CN108290958B/zh active Active
- 2016-09-30 EP EP16775695.6A patent/EP3356420B1/en active Active
- 2016-09-30 WO PCT/EP2016/073410 patent/WO2017055539A1/en not_active Ceased
- 2016-09-30 US US15/281,542 patent/US20170129962A1/en not_active Abandoned
-
2022
- 2022-01-27 US US17/586,455 patent/US20220363771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535196A5 (enExample) | ||
| JP2017522888A5 (enExample) | ||
| JP2022088627A (ja) | 多重特異性および多機能性分子ならびにその使用 | |
| JP7274413B2 (ja) | ラムダ及びカッパ軽鎖を含む多重特異性抗体分子 | |
| JP2020122013A5 (enExample) | ||
| US9771425B2 (en) | Anti-PD-1 antibodies | |
| JP2021530246A (ja) | 抗ｔｃｒ抗体分子およびその使用 | |
| JP2023100868A (ja) | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 | |
| JP2022523197A (ja) | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP2020023523A5 (enExample) | ||
| JP2022521750A (ja) | カルレティキュリンに結合する多機能性分子およびその使用 | |
| IL269270B (en) | Method and preparations for cellular immunotherapy | |
| JP2019527543A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| CN114127111A (zh) | 与nkp30结合的抗体分子及其用途 | |
| EP3707162A1 (en) | Il2rbeta/common gamma chain antibodies | |
| TW201815825A (zh) | 經修飾之抗原結合fab片段及包含其之抗原結合分子 | |
| JP2018512856A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2019530431A5 (enExample) | ||
| WO2020094834A1 (en) | Il2rbeta/common gamma chain antibodies | |
| JP2018521691A5 (enExample) | ||
| RU2012118636A (ru) | Молекула, специфически связывающаяся с rsv | |
| CA3164972A1 (en) | Materials and methods for in vivo biological targeting |